Jointown(SH:600998) China Post Securities·2025-10-29 08:25Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [6][13]. Core Insights - The company's Q3 performance exceeded expectations, with a notable improvement in cash flow. For the first three quarters of 2025, the company achieved a revenue of 1193.27 billion yuan, representing a year-on-year growth of 5.20%, and a net profit attributable to shareholders of 19.75 billion yuan, up by 16.46% [3][5]. - The company has shown strong growth in high-margin businesses, with significant revenue increases in pharmaceutical distribution and emerging sectors such as drug promotion and digital logistics, which grew by 15.26%, 9.93%, and 24.95% respectively [5]. - The issuance of public REITs has positively impacted net profit by 4.38 billion yuan, contributing to the overall financial health of the company [5]. Financial Performance Summary - For Q3 2025, the company reported revenues of 382.2 billion yuan, with a quarter-on-quarter growth of 5.41%. The net profit attributable to shareholders for the same period was 5.3 billion yuan, reflecting an 8.46% increase [4]. - The gross margin for the first three quarters of 2025 was 7.76%, with a net profit margin of 1.66% [4]. - The company is projected to achieve revenues of 1640.51 billion yuan, 1773.30 billion yuan, and 1916.34 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding net profits of 25.09 billion yuan, 27.60 billion yuan, and 30.46 billion yuan [6][9].